The prognosis of CML is good, with traditional treatments typically providing a substantial increase in life expectancy. Studies show that, depending on the stage of CML, the sudden introduction of multi-agent chemotherapy can delay the advancement of the disease and even lead to a complete remission. Furthermore, newer treatments, such as tyrosine kinase inhibitors (TKIs), have provided an additional benefit in CML. These medications have been able to control and actually prevent the progression of the disease, along with providing a much higher success rate in achieving complete remission.
When it comes to life expectancy, CML can, in some cases, extend life expectancy. Studies have shown that traditional chemotherapies can result in a five-year patient survival rate of up to 80 percent. With the newer treatments, such as TKIs, the five-year survival rate is even higher, with some patients being able to expect a life expectancy of up to 90-95 percent.
Beyond being able to extend life expectancy, treatments can also help improve the quality of life. With traditional chemotherapy, some of the newer treatments, and the advances in medical technology, CML patients are able to experience fewer side effects and improved overall health. The frequency with which CML patients require hospitalization is usually greatly reduced, depending on the stage of disease, and any hospitalizations often last only a few days. CML patients may also find that their quality of life drastically improves—they are able to enjoy their hobbies, stay socially connected, and pursue activities without the risk of advancement of the disease.
Overall, CML patients are usually able to return to a normal life with a much improved life expectancy. However, it is important to speak to a qualified medical professional for guidance specific to a CML patient’s individual condition.
Article Created by A.I.